Tag Archives: Big Pharma

New Non-Profit Alliance of Big Pharma Firms

By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
Posted in Biotech, Deals, Guest Blog | Also tagged , , , , , , , , , | Leave a comment

Measuring Responsibility in Big Pharma

Measuring Responsibility in Big Pharma If you can’t measure it, the saying goes, it doesn’t count.  But what if you’re measuring the wrong things? The Access to Medicines Index (www.accesstomedicineindex.org) is an attempt to measure and compare the corporate social responsibility of both innovator (20) and generics (7) companies based on a number of different […]
Posted in Corporate Responsibility, Guest Blog, healthcare | Also tagged , , , , | Leave a comment

Pharma Surges Ahead in Online Communications

It may surprise some working in the industry, but pharmaceutical companies, in particular those in Europe, rank among the world’s best online corporate communicators, writes David Bowen. Big Pharma has emerged as among the top online performers in the latest Financial Times–Bowen Craggs Index of web effectiveness, which examines the ‘web estates’ of 81 of […]
Posted in Guest Blog, Technology | Also tagged , , | Leave a comment

The Seven-Billion Society: What's In It For Pharma?

On Monday, the world’s population hit the 7 billion mark, repeating a pattern of largely unrestrained growth that has endured for the last century: the world is now adding roughly one billion people every 12 years. The UN Population Fund (UNPF) estimates that, barring some unforeseen demographic or environmental/development shifts, the figure will reach just […]
Posted in Global, healthcare, Op-Ed | Also tagged , , , | 1 Comment

Tufts R&D Outlook for 2011: Pain Mixed with Promise

The Tufts Center for Drug Development issues its annual assessment of the state of R&D in Big Pharma, noting that industry faces a cumulative tide of challenges marked by a dramatic reversal in societal attitudes toward risk. Productivity gaps in the pipeline aside, perhaps the biggest problem is political — convincing stakeholders to strive for […]
Posted in FDA, Gene therapy, R&D, Regulatory | Also tagged , , , , , | 1 Comment
  • Categories

  • Meta